<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329783</url>
  </required_header>
  <id_info>
    <org_study_id>A4001104</org_study_id>
    <nct_id>NCT01329783</nct_id>
  </id_info>
  <brief_title>EuroSIDA As An External Comparator To MOTIVATE Trials</brief_title>
  <official_title>Incidence And Risk Factors For Acquired Immune Deficiency Syndrome (AIDS) Defining And Non-AIDS Defining Malignancies, And Other AIDS Defining Illnesses In The EuroSIDA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen HIV Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Immunodeficiency Virus (HIV) infected patients who meet the entry criteria for the
      maraviroc pivotal trials (Maraviroc versus Optimized Therapy in Viremic Antiretroviral
      Treatment-Experienced Patients, MOTIVATE) will be identified from the EuroSIDA HIV cohort.
      The rates of specific clinical adverse events in this identified patient population will be
      compared with the rates of these events in the participants of the MOTIVATE trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients in EuroSIDA cohort that meet the entry criteria of MOTIVATE trials are included
      without any sampling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Malignancy</measure>
    <time_frame>Median follow up of 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Opportunistic infection</measure>
    <time_frame>Median follow up of 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>Median follow up of 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause death</measure>
    <time_frame>Median follow up of 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver related death</measure>
    <time_frame>Median follow up of 3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1181</enrollment>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>EuroSIDA sub-cohort</arm_group_label>
    <description>HIV infected patients in the EuroSIDA cohort who meet the entry criteria for maraviroc pivotal clinical trials (MOTIVATE 1 and MOTIVATE 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maraviroc</intervention_name>
    <description>No intervention is distributed during this trial.</description>
    <arm_group_label>EuroSIDA sub-cohort</arm_group_label>
    <other_name>Selzentry, Celsentri</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patient aged over 16 at baseline.

          -  Viral Load (VL) &gt; 5000 copies/ml at baseline (and measured in 6 months prior to
             baseline).

          -  No changes in antiretroviral (ARV) regimens in the month period prior to baseline, or
             on no ARVs in the month prior to baseline.

          -  &gt; 3 months exposure (sequential or cumulative) to at least 3 of the following;

          -  Any nucleoside or nucleotide reverse transcriptase inhibitor (NRTI)

          -  Non-nucleoside reverse transcriptase inhibitor (NNNRTI)

          -  Protease Inhibitor (PI )

          -  Enfuvirtide
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged over 16 at baseline.

          -  Viral Load (VL) &gt; 5000 copies/ml at baseline (and measured in 6 months prior to
             baseline).

          -  No changes in antiretroviral (ARV) regimens in the month period prior to baseline, or
             on no ARVs in the month prior to baseline.

          -  &gt; 3 months exposure (sequential or cumulative) to at least 3 of the following;

          -  Any nucleoside or nucleotide reverse transcriptase inhibitor (NRTI)

          -  Non-nucleoside reverse transcriptase inhibitor (NNNRTI)

          -  Protease Inhibitor (PI )

          -  Enfuvirtide

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001104&amp;StudyName=EuroSIDA%20As%20An%20External%20Comparator%20To%20MOTIVATE%20Trials</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

